+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fertility Testing Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • ID: 4622370
  • Report
  • February 2021
  • Region: Global
  • 120 pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Advacare Pharma
  • Babystart
  • Church & Dwight Co. Inc.
  • Fairhaven Health LLC
  • Fertility Focus Limited
  • Geratherm Medical AG
The global Fertility Testing Devices Market is poised to grow at a CAGR of 6.3% over the forecast period with a revenue of approximately USD 450 million in 2020 and is estimated to reach 645 million by 2026.

The contagious coronavirus has a potential economic impact and implications on most of the sectors. Human reproduction societies have issued guidelines for practice during the COVID-19 pandemic that include implementation of mitigation practices and infection control protocols infertility care units. However, the fertility test kits and devices have increased as the birth rate has increased during the lockdown period.

Declining fertility rates are a rising concern, globally. The declining fertility rates, owing to the rising first-time pregnancy age and high prevalence of PCOS (polycystic ovary syndrome) among women, are expected to support the growth of the market. In 2017, The United States experienced a record low for a second straight year, extending a deep decline that began in 2008, with the "Great Recession". However, fertility rates in the elderly population have been on a rise, over the past few years, owing to increasing awareness about fertility testing.

In Europe, the average fertility rate is 1.6. The lowest fertility rates were recorded in the southern European countries of Italy, Spain, and Portugal, where they range between 1.34 and 1.36, according to Eurostat, 2018.

Fertility rates in China are also decreasing. In China, the low fertility rate is a more serious problem than the aging population. According to the National Bureau of Statistics of China, 17.23 million newborns were added to China's population last year, down 630,000 year-on-year, and the birth rate dropped from 1.295% in 2016 to 1.243% in 2017. Hence, the decreasing fertility rates and increasing lifestyle disorders among women is expected to drive the market during the forecast period.

There are several computerized fertility monitors that are used to detect urinary LH and estrone‐3‐glucoronide, which, if presented in urine, indicates ovulation. For example, Clearblue DIGITAL Ovulation Test with Dual Hormone Indicator, of SPD Swiss Precision Diagnostics GmbH, detects estrogen as well as LH, claims that the product can identify four or more fertile days with an accuracy rate of over 99%, however, these digital kits are not affordable in many countries due to the financial barriers. The growing advancements in the test kits with the increasing launches boost the market growth.

Key Market Trends

Ovulation Prediction Kits are Expected to Witness Healthy Growth Over the Forecast Period

The pandemic has shown a mixed effect on the segment, as many couples have planned to have a baby during the pandemic due to lockdown in few countries whereas, many organizations estimate a fewer million fewer babies due to the pandemic. For instance, according to UNICEF, an estimated 116 million babies will be born during the COVID-19 pandemic.

Reproductive health organizations are recommending, out of caution and concern for lack of data, that couples planning pregnancies may hold off for the time being. The European Society of Human Reproduction and Embryology states that all fertility patients considering or planning treatment, even if they do not meet the diagnostic criteria for COVID-19 infection, should avoid becoming pregnant at this time.

OPKs or Ovulation prediction kits are used to detect the exact day of ovulation for a woman who is planning her pregnancy. There are many different kinds of ovulation prediction kits in the market. Most of the kits work by measuring the luteinizing hormone (LH) in the urine. LH levels rise 24-36 hours before ovulation. The high level of LH indicates that the release of the egg (ovulation) usually occurs 12-24 hours after the test turns positive.

According to the Centers for Disease Control, one in eight couples have trouble conceiving or sustaining a pregnancy, due to age, health issues, or other factors. This indicates that there is a need in the market for cost-efficient and accurate ovulation monitors. As the OPK provides cost-effective fertility testing, its demand is increasing.

United States Holds the Significant Revenue Share in the North America Region

In June 2021, the Brookings Institution estimated that in the United States, due to public health crisis and associated recession would result in 300,000 to 500,000 fewer births in 2021. According to the Guttmacher Institute survey, 2020, 34 percent of American women have either delayed their plans to have a child or reduced the number of children they expect to have as a result of the pandemic.

In 2018, the United States experienced a record low fertility rates. The fertility rate in the United States, in 2018, was 1.776 births per woman, a 1.11% decline from 2017 (1.796). The number of births in the country dropped by 2% between 2016 and 2017, to 60.2 births per 1,000 women aged 15-44 years, continuing a general downturn that started with the Great Recession of 2008. This marks the lowest that the fertility rate of the country has been in 30 years. According to the National Center for Health Statistics (2017), birthrates declined to record lows in all groups under age 30. Among women aged 20-24 years, the decline was 4%. For women aged 25-29 years, the rate fell to 2%.

According to the CDC, 2019, about 6% of married women aged 15-44 years in the United States are unable to get pregnant after one year of trying. Also, about 12% of women aged 15-44 years in the United States have difficulty getting pregnant or carrying a pregnancy, regardless of marital status.

Hence, the decreasing fertility rates and rising awareness about fertility testing are driving the fertility testing device market in the country.

Competitive Landscape

The market studied is moderately competitive and there are several local as well as international companies present in the market. Several companies are focusing on the new product launches to sustain their competitiveness and it has been observed that few new companies are entering the market studied which is increasing the competition.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Advacare Pharma
  • Babystart
  • Church & Dwight Co. Inc.
  • Fairhaven Health LLC
  • Fertility Focus Limited
  • Geratherm Medical AG
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Decreasing Fertility Rates
4.2.2 Rising Awareness about Fertility Testing Devices
4.2.3 Launch of Advanced, Easy-to-use Fertility Monitors With High Accuracy
4.3 Market Restraints
4.3.1 High Price of Ovulation Monitors
4.3.2 Lack of Predictive Accuracy to Confirm Ovulation
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Ovulation Prediction Kits
5.1.2 Fertility Monitors
5.1.2.1 Urine-based Ovulation Kits
5.1.2.2 Saliva-based Ovulation Kits
5.1.2.3 Other Fertility Monitors
5.1.3 Male Fertility Testing Products
5.2 By Mode of Purchase
5.2.1 OTC-based
5.2.2 Prescription-based
5.3 By Application
5.3.1 Female Fertility Testing
5.3.2 Male Fertility Testing
5.4 By End User
5.4.1 Home Care Settings
5.4.2 Hospitals/Fertility Clinics
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 COMPANY PROFILES
6.1.1 Church & Dwight Co. Inc.
6.1.2 Fairhaven Health LLC
6.1.3 Fertility Focus Limited
6.1.4 Geratherm Medical AG
6.1.5 HiLin Life Products Inc.
6.1.6 Prestige Brands Holdings Inc.
6.1.7 Quidel Corporation
6.1.8 Swiss Precision Diagnostics GmbH
6.1.9 Advacare Pharma
6.1.10 Babystart
6.1.11 Biozhena
6.1.12 Alere Inc.
6.1.13 Procter & Gamble Company
6.1.14 Uebe Medical GmbH
6.1.15 Samplytics Technologies Private Limited.
6.1.16 Tempdrop LLC
6.1.17 Valley Electronics
6.1.18 PREGMATE
6.1.19 Ava Science Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
  • Church & Dwight Co. Inc.
  • Fairhaven Health LLC
  • Fertility Focus Limited
  • Geratherm Medical AG
  • HiLin Life Products Inc.
  • Prestige Brands Holdings Inc.
  • Quidel Corporation
  • Swiss Precision Diagnostics GmbH
  • Advacare Pharma
  • Babystart
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll